Pathologic diagnosis of malignant mesothelioma: chronological prospect and advent of recommendations and guidelines.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Annali dell'Istituto Superiore di Sanità

• Publication date

  2015-03-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.4415/ANN_15_01_09PMID 25857384
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pulmonary Pathology

  2020cited by this paper
• The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.

  2013cited by this paper
• Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

  2013cited by this paper
• Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers

  2013cited by this paper
• Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update.

  2013cited by this paper
• Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: Trends in Australia and a literature review

  2013cited by this paper
• Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.

  2013influential reference
• Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendations.

  2013influential reference
• Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma.

  2012cited by this paper
• Is there a need for expert opinion for biopsy diagnosis of difficult cases of malignant mesothelioma?

  2012cited by this paper
• Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma

  2011cited by this paper
• Cytologic re-evaluation of negative effusions from patients with malignant mesothelioma.

  2011cited by this paper
• Expert Opinions of the First Italian Consensus Conference on the Management of Malignant Pleural Mesothelioma

  2011cited by this paper
• Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cited by this paper
• The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma

  2010cited by this paper
• Application of immunohistochemistry to the diagnosis of malignant mesothelioma.

  2009cited by this paper
• Protocol for the examination of specimens from patients with malignant pleural mesothelioma: a basis for checklists. Cancer Committee, College of American Pathologists.

  2009cited by this paper
• Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.

  2009cited by this paper
• Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma

  2009cited by this paper
• Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

  2008cited by this paper
• Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

  2008cited by this paper
• BTS statement on malignant mesothelioma in the UK, 2007

  2007cited by this paper
• What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update.

  2007cited by this paper
• Evidence-based Guidelines for the Utilization of Immunostains in Diagnostic Pathology: Pulmonary Adenocarcinoma Versus Mesothelioma

  2007cited by this paper
• Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

  2007cited by this paper
• Recommendations for the reporting of pleural mesothelioma

  2007cited by this paper
• Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data

  2006cited by this paper
• Minimum Clinical Recommendations for diagnosis, treatment and follow-up of malignant pleural mesothelioma.

  2005cited by this paper
• Cytopathology of Asbestos-Associated Diseases

  2004cited by this paper
• Pathology of malignant mesothelioma.

  2004cited by this paper
• Linee guida per la rilevazione e la definizione dei casi di mesotelioma maligno e la trasmissione delle informazioni all'Ispesl da parte dei Centri Operativi Regionali. seconda edizione

  2004cited by this paper
• Malignant mesothelioma

  2001cited by this paper
• Pathology of human malignant mesothelioma--preliminary analysis of 1,517 mesothelioma cases.

  2001cited by this paper
• Statement on malignant mesothelioma in the United Kingdom

  2001cited by this paper
• Statement on malignant mesothelioma in the United Kingdom.

  2001cited by this paper
• [Management of patients with malignant mesothelioma of the pleura].

  2000influential reference
• Protocol for the examination of specimens from patients with malignant pleural mesothelioma: a basis for checklists. Cancer Committee, College of American Pathologists.

  1999cited by this paper
• Histological Typing of Lung and Pleural Tumours

  1999cited by this paper
• Standards, Options et Recommandations pour la prise en charge des patients atteints de mésothéliome malin de la plèvre

  1998cited by this paper
• [Standards, Options, and Recommendations for the management of patients with malignant mesothelioma of the pleura. Fédération Nationale des Centres de Lutte Contre le Cancer].

  1998cited by this paper
• Newly marketed tissue markers for malignant mesothelioma: immunoreactivity of rabbit AMAD-2 antiserum compared with monoclonal antibody HBME-1 and a review of the literature on so-called antimesothelioma antibodies.

  1997cited by this paper
• Malignant mesothelioma of the pleura. The reproducibility of the immunohistological diagnosis.

  1997cited by this paper
• Calretinin: a novel immunocytochemical marker for mesothelioma.

  1996cited by this paper
• The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type.

  1996cited by this paper
• Malignant mesothelioma of the pleura: interobserver variability.

  1995cited by this paper
• Tumors of the serosal membranes

  1995cited by this paper
• Im mesotelioma maligno della pleura

  1994cited by this paper
• [Malignant mesothelioma].

  1994cited by this paper
• Diagnostic Criteria for Human Diffuse M a lignant Mesothelioma

  1992cited by this paper
• Malignant mesothelioma of the pleura.

  1988cited by this paper
• Recommended health-based occupational exposure limits for respiratory irritants

  1985cited by this paper
• Mesodermomas: a new embryological approach to primary tumours of coelomic surfaces

  1981cited by this paper
• Pathology of human malignant mesothelioma.

  1981cited by this paper
• Mesothelioma in man and experimental animals.

  1980cited by this paper
• CONTRIBUTION OF ELECTRON MICROSCOPY TO THE DIAGNOSIS OF PLEURAL MESOTHELIOMA *

  1979cited by this paper
• Absence of carcinoembryonic antigen‐like material in mesothelioma An immunohistochemical differentiation from other lung cancers

  1979cited by this paper
• Diffuse Pleural Mesothelioma in Trieste. A Survey Based on Autopsy Cases

  1978cited by this paper
• Considerations and proposals about mesotheliomas based on their morphological appearances. Note I. Histological considerations in optic microscopy.

  1977cited by this paper
• Public health risks of exposure to asbestos. Report of a Working Group of experts prepared for the Commission of the European Communities, Directorate-General for Social Affairs, Health and Safety Directorate.

  1977cited by this paper
• Ultrastructure of human mesotheliomas.

  1974cited by this paper
• Histochemistry in the diagnosis of malignant mesothelioma.

  1973cited by this paper
• Epidemiology of pleural mesothelioma in North-western Italy (Piedmont)

  1972cited by this paper
• Advances in surgical pathology.

  1968cited by this paper
• Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province

  1960cited by this paper
• Pleural neoplasms.

  1957cited by this paper
• Pathology of Tumours

  1948cited by this paper

• Ascites as a Rare Manifestation of Malignant Peritoneal Mesothelioma: A Case Report

  2024cites this paper
• Dissecting and Reconstructing Matrix in Malignant Mesothelioma Through Histocell-Histochemistry Gradients for Clinical Applications

  2022cites this paper
• Incidence, Survival Analysis and Future Perspective of Primary Peritoneal Mesothelioma (PPM): A Population-Based Study from SEER Database

  2022cites this paper
• An integrative histopathologic clustering model based on immuno‐matrix elements to predict the risk of death in malignant mesothelioma

  2020cites this paper
• Caso Clínico: Mesotelioma primario de pericardio

  2020cites this paper
• Predicting cancer using supervised machine learning: Mesothelioma

  2020cites this paper
• The Perception Approach: Level of Observer Variability Rating and Fusion Diagnoses.

  2019cites this paper
• Prognosticating Mesothelioma Using Predictive Analytics

  2019cites this paper
• Pleural diffuse mesothelial lesions: A challenge for pathologists

  2018influential citation
• Diagnosis of mesothelioma with deep learning

  2018influential citation
• Clustering of malignant pleural mesothelioma in asbestos factories: a subgroup analysis in a 29-year follow-up study to identify high-risk industries in Taiwan

  2018cites this paper
• Level of interobserver variability estimation as a valuable tool: assessment of tumour budding in colon cancer

  2018cites this paper
• CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives

  2017cites this paper
• Peritoneal Mesothelioma Presenting as Acute Abdominal Pain Secondary to Bowel Perforation

  2017cites this paper
• The Role of CD90 in the Differential Diagnosis of Pleural Malignant Mesothelioma, Pulmonary Carcinoma and Comparison with Calretının

  2017cites this paper